ArticleJournal of gastrointestinal oncology2019
Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy.
Article in Journal of gastrointestinal oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02620527 (Study of Concordance Between Circulating Tumor DNA Assay and Foundation One Tissue Analysis For Genomic Alterations), which is not on this map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study of Concordance Between Circulating Tumor DNA Assay and Foundation One Tissue Analysis For Genomic Alterations
Who cites it
25 citing papers in PubMed, 38 citations in OpenAlex.
- Review
- Recent Technologies towards Diagnostic and Therapeutic Applications of Circulating Nucleic Acids in Colorectal Cancers.International journal of molecular sciences · 2024Review
- Circulating tumour DNA alterations: emerging biomarker in head and neck squamous cell carcinoma.Journal of biomedical science · 2023Review
- Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.Nature communications · 2023Article
- Article
- Clinical utility of liquid biopsy and integrative genomic profiling in early-stage and oligometastatic cancer patients treated with radiotherapy.British journal of cancer · 2023Article
- Genomic landscape of 891 RET fusions detected across diverse solid tumor types.NPJ precision oncology · 2023Article
- Clinical application of liquid biopsy based on circulating tumor DNA in non-small cell lung cancer.Frontiers in physiology · 2023Review
- Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study.Annals of oncology : official journal of the European Society for Medical Oncology · 2023Article
- Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors.NPJ precision oncology · 2022Article
- Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples.JCO precision oncology · 2022Article
- The current state of molecular profiling in gastrointestinal malignancies.Biology direct · 2022Review
- Dynamic liquid biopsy components as predictive and prognostic biomarkers in colorectal cancer.Journal of experimental & clinical cancer research : CR · 2022Review
- The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Recent Advances in Pediatric Cancer Research.Cancer research · 2021Review
- Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA.NPJ precision oncology · 2021Article
- Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development.Nature reviews. Clinical oncology · 2021Review
- Identification of germline cancer predisposition variants during clinical ctDNA testing.Scientific reports · 2021Article
- Updates on Clinical Use of Liquid Biopsy in Colorectal Cancer Screening, Diagnosis, Follow-Up, and Treatment Guidance.Frontiers in cell and developmental biology · 2021Review
- Intra-Tumor Heterogeneity of Colorectal Cancer Necessitates the Multi-Regional Sequencing for Comprehensive Mutational Profiling.Cancer management and research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 8 institutions in 1 country.
Funding
Abstract
backgroundLiquid biopsy offers the ability to non-invasively analyze the genome of a tumor through circulating tumor DNA (ctDNA) to identify targetable and prognostic genomic alterations. Few studies have rigorously analyzed ctDNA results and determined the fidelity with which they recapitulate the genomics of a sequenced tissue sample obtained from the same tumor. The clinical utility study (CUS) for the FoundationACT™ ctDNA assay (Foundation Medicine, Cambridge, MA, USA; NCT02620527) is a multi-center prospective clinical study for multiple solid tumor types to compare genomic profiling of paired tissue and blood samples from the same patient. In this subset of the study, paired specimens from 96 patients with colorectal cancer (CRC) were analyzed with comprehensive genomic profiling (CGP) of the tumor tissue sample (FoundationOne
methodsBoth samples underwent CGP using the hybrid capture-based Illumina Hi-Seq technology. Maximum somatic allele frequency (MSAF) was used to estimate the fraction of ctDNA in the sample. The set of genes and targeted regions common to both tumor and liquid were compared for each subject.
resultsAmong these patients, 61% were male; 74% had clinical stage IV disease, 19% had clinical stage III disease, and 7% had clinical stage II disease. Time between the tissue biopsy and liquid biopsy (range, 0
conclusionsIn cases where tumor tissue profiling is not possible, these results provide compelling evidence that genomic profiling of ctDNA in late stage CRC shows a high concordance with tumor tissue sequencing results and can be used to identify most clinically relevant alterations capable of guiding therapy for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.